Rexahn Pharmaceuticals, Inc. (RNN) Rating Lowered to Hold at Zacks Investment Research
According to Zacks, “REXAHN PHARMACTICALS is a biopharmaceutical company leveraging its proprietary technology platform to discover, develop and commercialize innovative treatments for cancer, central nervous system disorders, sexual dysfunction and other unmet medical needs. Rexahn’s compounds are designed to uniquely treat various disease states while significantly minimizing side effects in order to allow patients to regain quality of life through therapy. “
Separately, FBR & Co restated an outperform rating and issued a $3.00 price objective on shares of Rexahn Pharmaceuticals in a report on Wednesday, October 5th.
Rexahn Pharmaceuticals (NYSE:RNN) opened at 0.1799 on Wednesday. Rexahn Pharmaceuticals has a one year low of $0.16 and a one year high of $0.52. The firm’s 50-day moving average price is $0.22 and its 200 day moving average price is $0.27. The company’s market capitalization is $38.37 million.
Rexahn Pharmaceuticals (NYSE:RNN) last released its earnings results on Monday, August 8th. The company reported ($0.01) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.02) by $0.01. On average, equities research analysts expect that Rexahn Pharmaceuticals will post ($0.07) earnings per share for the current fiscal year.
An institutional investor recently raised its position in Rexahn Pharmaceuticals stock. Vanguard Group Inc. increased its position in Rexahn Pharmaceuticals, Inc. (NYSE:RNN) by 1.0% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 4,904,097 shares of the company’s stock after buying an additional 49,761 shares during the period. Vanguard Group Inc. owned about 2.30% of Rexahn Pharmaceuticals worth $1,232,000 as of its most recent filing with the SEC.
Rexahn Pharmaceuticals Company Profile
Rexahn Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company engaged in the discovery, development and commercialization of treatments for cancer. The Company’s clinical-stage drug candidates in active development include Archexin, RX-3117 and Supinoxin (RX-5902). Archexin is a potent inhibitor of the protein kinase Akt-1, which focuses on cancer cell proliferation, survival, angiogenesis, metastasis and drug resistance.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Rexahn Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rexahn Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.